A Polyphenol-Based Multicomponent Nutraceutical in Dysmetabolism and Oxidative Stress: Results from a Pilot Study

ABSTRACT

To assess short-term efficacy and safety of a multicomponent nutraceutical (MCN) on dysmetabolism and oxidative stress, a pilot prospective observational study was performed on 21 individuals (12 men and 9 women) who took, for 60 days, 2 tablets per day of an MCN based on antioxidants and metabolism regulators: hydroxytyrosol (15 mg), maqui (300 mg), amla (200 mg), monacolin K (10 mg), berberine (245 mg), astaxanthin (0.5 mg), coenzyme Q10 (100 mg), and folic acid (200 mcg). On day 0 (T0) and day 60 (T60), all participants underwent laboratory tests related to lipid profile, carbohydrate metabolism, oxidative stress, and cellular inflammation. Statistical analysis was applied to the resulting data. A significant improvement of most atherogenesis and oxidative stress biomarkers was recorded (mean figure at T0 and T60, p value): total cholesterol 243.50/194.83 mg/dl, p =.0002; low-density lipoproteins 174.50/124.58 mg/dl, p =.0001; glycemia 96.25/88.50 mg/dl, p =.035; total free radicals 306.44/280.93 U.Carr., p =.036; serum antioxidant capacity 2103.00/2246.06 umol/l, p =.0042; oxidized cholesterol 680.33/597.25 uEq/l, p =.0511. Insulinemia, microalbuminuria, high-density lipoproteins, C-reactive protein, and triglycerides had no statistically significant variation. Body weight and systo-diastolic pressure showed no significant change from T0 to T60. No relevant side effects were reported. The investigated MCN (Eonlipid), based on polyphenols, significantly improved the oxidative stress parameters and decreased the majority of atherogenesis parameters at short term. No significant side effects were reported. Further placebo-controlled studies should possibly corroborate the promising results of this pilot study.

KEYWORDS:

• amla
• antioxidants
• atherogenesis
• hydroxytyrosol
• inflammaging
• lipid profile
• maqui
• monacolin K
• oxidative stress
• polyphenols
• free radicals

Declaration of interest

The authors have no potential conflict of interest that pertains to this article. Proeon srl provided all participants with the MCN Eonlipid free of charge; Proeon srl did not interfere with data collection, data analysis, or text compilation. No grant was provided from Proeon srl for the performance of the study.

About the authors

Roberto Corsi is an MD specialist in clinical pathology.

Giovanni Mosti is an MD specialist in cardiology and is dedicated especially to angiology.

Attilio Cavezzi, MD, is a vascular surgeon, vice-president of International Union of Phlebology, and also is dedicated to longevity medicine.

Simone Ugo Urso is an MD specialist in emergency surgery and is dedicated to nutrition and longevity medicine.

Gayla Dimitrova, BS, is a management collaborator of Eurocenter Venalinfa.

Elena Fioroni, MS, is a biologist responsible for blood analysis.

Roberto Colucci, BS, is a management collaborator of Eurocenter Venalinfa.

Valentina Quinzi, MS, is a biologist involved in research about longevity medicine.